Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PetMed Express, Inc. and its officers or directors [1] Group 1: Company Actions - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [2] - Following the announcement, PetMed's stock price dropped by $0.47 per share, or 11.22%, closing at $3.72 per share on June 11, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

With a stellar track record and well-earned expertise in antitrust law and complex commercial litigation, Barry Barnett is one of Forbes' Best-In-State Lawyers 2025. https://t.co/CCjciGEHZq #ForbesTopLawyers ...

Core Viewpoint - A shareholder class action lawsuit has been filed against Civitas Resources, Inc. alleging misleading statements and failure to disclose adverse information regarding its business and operations [1] Group 1: Allegations in the Lawsuit - The lawsuit claims that Civitas is likely to significantly reduce its oil production in 2025 due to declines following the production peak at the DJ Basin in Q4 2024 and a low turned-in-lines count at the end of 2024 [1] - It is alleged that increasing oil production would require Civitas to acquire additional acreage and development locations, leading to significant debt and potential asset sales to offset acquisition costs [1] - The financial condition of Civitas may necessitate disruptive cost-reduction measures, including a significant workforce reduction [1] - Consequently, the lawsuit asserts that Civitas's business and financial prospects, as well as its operational capabilities, were overstated [1]

Core Insights - Holzer & Holzer, LLC is investigating whether Altimmune, Inc. complied with federal securities laws following the announcement of topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) [1] - The trial results indicated that there was no statistical significance in improving fibrosis without worsening MASH, leading to a decline in Altimmune's stock price [1] Company Overview - Altimmune, Inc. is a publicly traded company on NASDAQ under the ticker symbol ALT [1] - The company is currently facing scrutiny regarding its compliance with federal securities laws due to the recent trial results [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Elevance common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

Core Insights - Holzer & Holzer, LLC is investigating Ichor Holdings, Ltd. for potential compliance issues with federal securities laws following disappointing Q1 2025 financial results [1] - Ichor's CEO indicated that the company's strategy did not yield the expected margin flow due to higher-than-forecasted external supply purchases [1] - The announcement of these results led to a decline in Ichor's stock price [1] Company Overview - Ichor Holdings, Ltd. trades on NASDAQ under the ticker ICHR [1] - The company reported its Q1 2025 financial results on May 5, 2025 [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in various legal actions [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Insights - Holzer & Holzer, LLC is investigating Myriad Genetics for potential compliance issues with federal securities laws following a significant decline in pharmacogenomics revenue [1] - Myriad Genetics reported a 20% year-over-year decline in pharmacogenomics revenue attributed to UnitedHealthcare reducing coverage of GeneSight [1] - The company's stock price dropped after the announcement of its first quarter 2025 financial results and lowered financial guidance [1]

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Krispy Kreme, Inc. (NASDAQ: DNUT) between February 25, 2025 and May 7, 2025, both dates inclusive (the “Class Period”), of the important July 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased Krispy Kreme securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

MILWAUKEE, June 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Guaranty (NYSE: GNTY) for possible breaches of fiduciary duty and other violations of law in its transaction with Glacier Bancorp.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.  There is no cost or obligation to you.In the tender offer transaction, shareholders of Guaranty will receive 1.0000 share of Glacier stock for each Guaranty shar ...

Core Viewpoint - A class action lawsuit has been filed against Compass Group Diversified Holdings LLC due to alleged failures in financial reporting and internal controls, leading to significant stock price decline following the revelation of these issues [3][4][5]. Group 1: Lawsuit Details - The class action lawsuit, Nicholas Moreno v. Compass Group Diversified Holdings LLC, has been amended and is ongoing in the United States District Court for the District of Connecticut [1]. - The lawsuit pertains to securities purchased between February 24, 2022, and May 7, 2025, and claims that Compass failed to disclose critical information regarding its subsidiary, Lugano Holding, Inc. [1][3]. Group 2: Financial Reporting Issues - Compass Group's internal controls over financial reporting were deemed ineffective, and undisclosed financing arrangements related to Lugano were highlighted as problematic [3]. - The company announced on May 7, 2025, that its financial statements for fiscal 2024 could no longer be relied upon due to an internal investigation into Lugano's financing of inventory [4]. Group 3: Stock Price Impact - Following the announcement of the investigation, Compass' stock price plummeted from $17.25 per share on May 7, 2025, to $6.55 per share on May 8, 2025, indicating a dramatic loss in market value [5].